Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1

Celine V M Cluzeau, Dawn E. Watkins-Chow, Rao Fu, Bhavesh Borate, Nicole Yanjanin, Michelle K. Dail, Cristin D. Davidson, Steven U. Walkley, Daniel S. Ory, Christopher A. Wassif, William J. Pavan, Forbes D. Porter

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Niemann-Pick disease type C (NPC) is a lysosomal storage disorder characterized by liver disease and progressive neurodegeneration. Deficiency of either NPC1 or NPC2 leads to the accumulation of cholesterol and glycosphingolipids in late endosomes and early lysosomes. In order to identify pathological mechanisms underlying NPC and uncover potential biomarkers, we characterized liver gene expression changes in an Npc1 mouse model at six ages spanning the pathological progression of the disease. We identified altered gene expression at all ages, including changes in asymptomatic, 1-week-old mice. Biological pathways showing early altered gene expression included: lipid metabolism, cytochrome P450 enzymes involved in arachidonic acid and drug metabolism, inflammation and immune responses, mitogen-activated protein kinase and G-protein signaling, cell cycle regulation, cell adhesion and cytoskeleton remodeling. In contrast, apoptosis and oxidative stress appeared to be late pathological processes. To identify potential biomarkers that could facilitate monitoring of disease progression, we focused on a subset of 103 differentially expressed genes that encode secreted proteins. Further analysis identified two secreted proteins with increased serum levels in NPC1 patients: galectin-3 (LGALS3), a pro-inflammatory molecule, and cathepsin D (CTSD), a lysosomal aspartic protease. Elevated serum levels of both proteins correlated with neurological disease severity and appeared to be specific for NPC1. Expression of Lgals3 and Ctsd was normalized following treatment with 2-hydroxypropyl-β-cyclodextrin, a therapy that reduces pathological findings and significantly increases Npc1-/- survival. Both LGALS3 and CTSD have the potential to aid in diagnosis and serve as biomarkers to monitor efficacy in therapeutic trials. Published by Oxford University Press 2012.

Original languageEnglish (US)
Article numberdds193
Pages (from-to)3632-3646
Number of pages15
JournalHuman Molecular Genetics
Volume21
Issue number16
DOIs
StatePublished - Aug 2012

Fingerprint

Type C Niemann-Pick Disease
Galectin 3
Microarray Analysis
Cathepsin D
Biomarkers
Gene Expression
Cytochrome P-450 Enzyme System
Disease Progression
Serum
Cyclic GMP-Dependent Protein Kinases
Glycosphingolipids
Proteins
Endosomes
Cyclodextrins
Pathologic Processes
Lysosomes
Mitogen-Activated Protein Kinases
Cytoskeleton
Lipid Metabolism
GTP-Binding Proteins

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Molecular Biology

Cite this

Cluzeau, C. V. M., Watkins-Chow, D. E., Fu, R., Borate, B., Yanjanin, N., Dail, M. K., ... Porter, F. D. (2012). Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1. Human Molecular Genetics, 21(16), 3632-3646. [dds193]. https://doi.org/10.1093/hmg/dds193

Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1. / Cluzeau, Celine V M; Watkins-Chow, Dawn E.; Fu, Rao; Borate, Bhavesh; Yanjanin, Nicole; Dail, Michelle K.; Davidson, Cristin D.; Walkley, Steven U.; Ory, Daniel S.; Wassif, Christopher A.; Pavan, William J.; Porter, Forbes D.

In: Human Molecular Genetics, Vol. 21, No. 16, dds193, 08.2012, p. 3632-3646.

Research output: Contribution to journalArticle

Cluzeau, CVM, Watkins-Chow, DE, Fu, R, Borate, B, Yanjanin, N, Dail, MK, Davidson, CD, Walkley, SU, Ory, DS, Wassif, CA, Pavan, WJ & Porter, FD 2012, 'Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1', Human Molecular Genetics, vol. 21, no. 16, dds193, pp. 3632-3646. https://doi.org/10.1093/hmg/dds193
Cluzeau CVM, Watkins-Chow DE, Fu R, Borate B, Yanjanin N, Dail MK et al. Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1. Human Molecular Genetics. 2012 Aug;21(16):3632-3646. dds193. https://doi.org/10.1093/hmg/dds193
Cluzeau, Celine V M ; Watkins-Chow, Dawn E. ; Fu, Rao ; Borate, Bhavesh ; Yanjanin, Nicole ; Dail, Michelle K. ; Davidson, Cristin D. ; Walkley, Steven U. ; Ory, Daniel S. ; Wassif, Christopher A. ; Pavan, William J. ; Porter, Forbes D. / Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1. In: Human Molecular Genetics. 2012 ; Vol. 21, No. 16. pp. 3632-3646.
@article{674cdbc7eda542e9a85626b37bab89b7,
title = "Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1",
abstract = "Niemann-Pick disease type C (NPC) is a lysosomal storage disorder characterized by liver disease and progressive neurodegeneration. Deficiency of either NPC1 or NPC2 leads to the accumulation of cholesterol and glycosphingolipids in late endosomes and early lysosomes. In order to identify pathological mechanisms underlying NPC and uncover potential biomarkers, we characterized liver gene expression changes in an Npc1 mouse model at six ages spanning the pathological progression of the disease. We identified altered gene expression at all ages, including changes in asymptomatic, 1-week-old mice. Biological pathways showing early altered gene expression included: lipid metabolism, cytochrome P450 enzymes involved in arachidonic acid and drug metabolism, inflammation and immune responses, mitogen-activated protein kinase and G-protein signaling, cell cycle regulation, cell adhesion and cytoskeleton remodeling. In contrast, apoptosis and oxidative stress appeared to be late pathological processes. To identify potential biomarkers that could facilitate monitoring of disease progression, we focused on a subset of 103 differentially expressed genes that encode secreted proteins. Further analysis identified two secreted proteins with increased serum levels in NPC1 patients: galectin-3 (LGALS3), a pro-inflammatory molecule, and cathepsin D (CTSD), a lysosomal aspartic protease. Elevated serum levels of both proteins correlated with neurological disease severity and appeared to be specific for NPC1. Expression of Lgals3 and Ctsd was normalized following treatment with 2-hydroxypropyl-β-cyclodextrin, a therapy that reduces pathological findings and significantly increases Npc1-/- survival. Both LGALS3 and CTSD have the potential to aid in diagnosis and serve as biomarkers to monitor efficacy in therapeutic trials. Published by Oxford University Press 2012.",
author = "Cluzeau, {Celine V M} and Watkins-Chow, {Dawn E.} and Rao Fu and Bhavesh Borate and Nicole Yanjanin and Dail, {Michelle K.} and Davidson, {Cristin D.} and Walkley, {Steven U.} and Ory, {Daniel S.} and Wassif, {Christopher A.} and Pavan, {William J.} and Porter, {Forbes D.}",
year = "2012",
month = "8",
doi = "10.1093/hmg/dds193",
language = "English (US)",
volume = "21",
pages = "3632--3646",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "16",

}

TY - JOUR

T1 - Microarray expression analysis and identification of serum biomarkers for niemann-pick disease, type c1

AU - Cluzeau, Celine V M

AU - Watkins-Chow, Dawn E.

AU - Fu, Rao

AU - Borate, Bhavesh

AU - Yanjanin, Nicole

AU - Dail, Michelle K.

AU - Davidson, Cristin D.

AU - Walkley, Steven U.

AU - Ory, Daniel S.

AU - Wassif, Christopher A.

AU - Pavan, William J.

AU - Porter, Forbes D.

PY - 2012/8

Y1 - 2012/8

N2 - Niemann-Pick disease type C (NPC) is a lysosomal storage disorder characterized by liver disease and progressive neurodegeneration. Deficiency of either NPC1 or NPC2 leads to the accumulation of cholesterol and glycosphingolipids in late endosomes and early lysosomes. In order to identify pathological mechanisms underlying NPC and uncover potential biomarkers, we characterized liver gene expression changes in an Npc1 mouse model at six ages spanning the pathological progression of the disease. We identified altered gene expression at all ages, including changes in asymptomatic, 1-week-old mice. Biological pathways showing early altered gene expression included: lipid metabolism, cytochrome P450 enzymes involved in arachidonic acid and drug metabolism, inflammation and immune responses, mitogen-activated protein kinase and G-protein signaling, cell cycle regulation, cell adhesion and cytoskeleton remodeling. In contrast, apoptosis and oxidative stress appeared to be late pathological processes. To identify potential biomarkers that could facilitate monitoring of disease progression, we focused on a subset of 103 differentially expressed genes that encode secreted proteins. Further analysis identified two secreted proteins with increased serum levels in NPC1 patients: galectin-3 (LGALS3), a pro-inflammatory molecule, and cathepsin D (CTSD), a lysosomal aspartic protease. Elevated serum levels of both proteins correlated with neurological disease severity and appeared to be specific for NPC1. Expression of Lgals3 and Ctsd was normalized following treatment with 2-hydroxypropyl-β-cyclodextrin, a therapy that reduces pathological findings and significantly increases Npc1-/- survival. Both LGALS3 and CTSD have the potential to aid in diagnosis and serve as biomarkers to monitor efficacy in therapeutic trials. Published by Oxford University Press 2012.

AB - Niemann-Pick disease type C (NPC) is a lysosomal storage disorder characterized by liver disease and progressive neurodegeneration. Deficiency of either NPC1 or NPC2 leads to the accumulation of cholesterol and glycosphingolipids in late endosomes and early lysosomes. In order to identify pathological mechanisms underlying NPC and uncover potential biomarkers, we characterized liver gene expression changes in an Npc1 mouse model at six ages spanning the pathological progression of the disease. We identified altered gene expression at all ages, including changes in asymptomatic, 1-week-old mice. Biological pathways showing early altered gene expression included: lipid metabolism, cytochrome P450 enzymes involved in arachidonic acid and drug metabolism, inflammation and immune responses, mitogen-activated protein kinase and G-protein signaling, cell cycle regulation, cell adhesion and cytoskeleton remodeling. In contrast, apoptosis and oxidative stress appeared to be late pathological processes. To identify potential biomarkers that could facilitate monitoring of disease progression, we focused on a subset of 103 differentially expressed genes that encode secreted proteins. Further analysis identified two secreted proteins with increased serum levels in NPC1 patients: galectin-3 (LGALS3), a pro-inflammatory molecule, and cathepsin D (CTSD), a lysosomal aspartic protease. Elevated serum levels of both proteins correlated with neurological disease severity and appeared to be specific for NPC1. Expression of Lgals3 and Ctsd was normalized following treatment with 2-hydroxypropyl-β-cyclodextrin, a therapy that reduces pathological findings and significantly increases Npc1-/- survival. Both LGALS3 and CTSD have the potential to aid in diagnosis and serve as biomarkers to monitor efficacy in therapeutic trials. Published by Oxford University Press 2012.

UR - http://www.scopus.com/inward/record.url?scp=84865066581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865066581&partnerID=8YFLogxK

U2 - 10.1093/hmg/dds193

DO - 10.1093/hmg/dds193

M3 - Article

C2 - 22619379

AN - SCOPUS:84865066581

VL - 21

SP - 3632

EP - 3646

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 16

M1 - dds193

ER -